Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05432167 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 195
- Enrollment target
NCT05432167 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 195 participants.
The verdict
NCT05432167, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 195 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of CIN-107 for the treatment of hypertension in patients with uncontrolled hypertension (uHTN) and Chronic Kidney Disease (CKD).
Interventions
- DRUG Placebo
- DRUG CIN-107
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 195 participants |
| Start Date | 2022-04-29 |
| Est. Completion | 2024-05-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05432167
The ClinicalTrials.gov registry entry for NCT05432167 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 195 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05432167 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05432167 about?
NCT05432167 is a clinical study titled "A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease". This study will evaluate the efficacy and safety of CIN-107 for the treatment of hypertension in patients with uncontrolled hypertension (uHTN) and Chronic Kidney Disease (CKD).
What is the current status of trial NCT05432167?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 195 participants. The study started on 2022-04-29. Estimated completion is 2024-05-02.
What interventions are being tested in trial NCT05432167?
The interventions under investigation include: Placebo (DRUG), CIN-107 (DRUG).
Who is sponsoring clinical trial NCT05432167?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.